Anna Greenshields

Anna Greenshields

Auto-generated profile, based on publicly available information

Anna Greenshields

Dalhousie University

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 January 2023 in Brazilian Journal of Transplantation
Verified
Journal Article
Open access
TSTiago Schiavo
Tiago Schiavo
JMJuliana Montagner
Juliana Montagner
EKElizete Keitel
Elizete Keitel
AGAnna Greenshields
Anna Greenshields
RLRobert S Liwski
Robert S Liwski
JNJorge Neumann
Jorge Neumann
Introduction: The main strategy to reduce the immunogenicity of transplanted grafts is to seek maximum compatibility between alloantigens in the donor-recipient pair. It is understood that the virtual crossmatch (VXM) can be a good tool in the evaluation of the donor / recipient pair and that a broader application of these protocols will improve the pre-transplant immunological risk assessment. The aim of this study was to correlate the physical flow crossmatches results, looking at different mean fluorescence intensity (MFI) values of the donor specific antibodies (DSA), and the probability of a positive crossmatch. We also aimed to validate this tool using a well standardized flow crossmatch protocol. Methods: We performed a total of 15,217 FCXM between 2015 and 2019. All were tested by the Halifax Flow Cytometer Crossmatch (FCXM) protocol, with cells from deceased donors and serum from renal recipients. For this analysis we selected only samples that had one or two DSA per locus (N = 1,081), when the MFI was above 1,000, and they were divided according to the allelic group recognized by the antibody (anti-HLA-A, B, C, DR or DQ) looking at the probability of a positive crossmatch with different MFI values of the DSAs. Combinations among them were also analyzed in the same way (N=175). Results: In the presence of an exclusive DSA against the allelic groups A, B and DR, with an index MFI above 5,000, all the FCXM were positives. With exclusively antibodies against groups C or DQ, all cases with DSAs above 15,000 MFIs were positives. With two or more DSAs anti A and/or B, and/or DR, when their MFIs sums exceeded 5,000, all FCXM results against B cells were positive. The presence of anti-Class I DSAs (A, B and A+B), regardless of the MFI value, was responsible for 71% (N=424 of 601) of the T cell positivity and 77% (N=460 of 661) in the B cell crossmatches. The presence of only anti-Class II DSAs (DR and DQ) accounted for 55% (N=168 of 303) of FCXM positivity in B cells. The overall mean of the MFI of the DSAs was higher in the FCXM positive group when compared to negative crossmatch. The group with sum of DSAs A (N=217) showed that when the sum was 4,000 MFI or higher, there was a 24 times higher probability for a positive B cell crossmatch when compared with lowers MFIs. Conclusions: Our results show a strong association between the DSA MFI and the FCXM result. The data here presented confirm the results of our previous studies, justifying the VXM standard used by our center, proving to be a good tool to streamline the selection of transplant recipients and facilitate the sharing of organs from national donors.

1 May 2016 in Stem Cell Research
Verified
Journal Article
Open access
PSP.A. De Sousa
P.A. De Sousa
BTB.J. Tye
B.J. Tye
KBK. Bruce
K. Bruce
PDP. Dand
P. Dand
GRG. Russell
G. Russell
ACA. Courtney
A. Courtney
The human embryonic stem cell line RCe018-A (RC-14) was derived under quality assured compliance with UK regulation, European Union Directives and International guidance for tissue procurement, processing and storage according to Good Manufacturing Practice (GMP) standards. The cell line was derived from a blastocyst stage embryo voluntarily donated as unsuitable or surplus to fertility requirements following informed consent. RCe018-A (RC-14) shows normal pluripotency marker expression and differentiation to the three germ layers in vitro. It has a male karyotype with an extra copy of chromosome 8 (47XY, +8). Microsatellite PCR identity, HLA and blood group typing data are available.

2 August 2024 in Human Immunology
Verified
Journal Article
Open access
MAManal Al Aufi
Manal Al Aufi
AGAnna L. Greenshields
Anna L. Greenshields
STSandra Tafulo
Sandra Tafulo
RLRobert S. Liwski
Robert S. Liwski
Compromised detection of HLA specific antibodies due to complement mediated interference (CMI) is a well-recognized limitation of the single antigen bead (SAB) assay. Serum treatment with EDTA prior to SAB assay testing is a common strategy used to prevent CMI, however, treatment of individual sera, especially in large clinical runs, can extend assay turnaround time and increase the risk of a sample mix-up. In this study, we describe a simplified EDTA treatment strategy that can be applied simultaneously to all sera in a testing run. This strategy effectively prevents CMI without added pipetting steps and the increased turnaround time associated with other strategies. In the novel bead treatment (BT) method, EDTA solution and SAB suspension are combined and added into the wells of a testing tray together, patient sera are then added to the SAB/EDTA mixture. This eliminates the separate EDTA pre-treatment step used in the standard procedure (ST). Parallel testing using the BT, ST, and no EDTA treatment strategies followed by antibody identification using the Rapid Optimized SAB (ROB) protocol was performed for 19 well characterized sera with known CMI at two different laboratories. Both BT and ST methods were equally effective in preventing CMI. In addition, excellent MFI correlation was observed for specificities not affected by CMI. Both negative and pooled positive control sera performed as expected using the BT method and the pooled positive control serum, specifically designed to exhibit CMI, served well as an EDTA treatment control for all sera. The modified BT protocol can be easily implemented for clinical testing and eliminates extra pipetting steps, reduces the likelihood of pipetting error, and decreases turnaround time, while effectively preventing CMI and ensuring accurate detection of HLA antibodies. This protocol was recently implemented in the Halifax HLA Laboratory and has been very positively received by the laboratory team.

20 September 2017
Verified
Conference Paper
Closed access
AGAnna Greenshields
Anna Greenshields
Welcome to the largest platform for early-stage research

25 January 2023 in Brazilian Journal of Transplantation
Verified
Journal Article
Open access
TSTiago Schiavo
Tiago Schiavo
JMJuliana Montagner
Juliana Montagner
EKElizete Keitel
Elizete Keitel
AGAnna Greenshields
Anna Greenshields
RLRobert S Liwski
Robert S Liwski
JNJorge Neumann
Jorge Neumann
Introdução: A principal estratégia para reduzir a imunogenicidade dos enxertos transplantados é buscar a máxima compatibilidade entre os aloantígenos no par doador-receptor. Entende-se que a prova cruzada virtual (VXM) pode ser uma boa ferramenta na avaliação da dupla doador/receptor e que uma aplicação mais ampla desses protocolos melhorará a avaliação do risco imunológico pré-transplante. O objetivo deste estudo foi correlacionar os resultados das provas cruzadas por citometria de fluxo (FCXM), observando os diferentes valores médios de intensidade de fluorescência (MFI) e o alvo dos anticorpos doador específicos (DSA), com a probabilidade de uma prova cruzada positiva. Usamos para isso o protocolo Halifax de prova cruzada por citometria de fluxo. Métodos: Foram realizados um total de 15.217 FCXM entre 2015 e 2019. Todos foram testados pelo protocolo Halifax Flow Cytometer Crossmatch (FCXM), com células de doadores falecidos e soro de receptores renais. Para esta análise, selecionamos apenas as amostras que apresentavam um ou dois DSAs por locus (N = 1.081) quando o MFI estava acima de 1.000. Esses foram divididos de acordo com o grupo alélico reconhecido pelo anticorpo (anti-HLA-A, B, C, DR ou DQ) observando a probabilidade de uma prova cruzada positiva com diferentes valores de MFI dos DSAs. As combinações entre eles também foram analisadas da mesma forma (N=175). Resultados: Na presença de um DSA exclusivo contra os grupos alélicos A, B e DR, com índice MFI acima de 5.000, todos os FCXM foram positivos. Com anticorpos exclusivamente contra os grupos C ou DQ, todos os casos com DSAs acima de 15.000 MFIs foram positivos. Com dois ou mais DSAs anti A e/ou B, e/ou DR, quando suas somas de MFIs excederam 5.000, todos os resultados de FCXM contra células B foram positivos. A presença de DSA anti-Classe I (A, B e A+B), independentemente do valor de MFI, foi responsável por 71% (N=424 de 601) da positividade de células T e 77% (N=460 de 661) nas células B. A presença apenas de DSAs anti Classe II (DR e DQ) foi responsável por 55% (N=168 de 303) da positividade FCXM em células B. A média geral do MFI dos DSAs foi maior no grupo FCXM positivo quando comparado ao crossmatch negativo. O grupo com somatória de DSAs A (N=217) mostrou que quando a soma era de 4.000 MFIs ou mais havia uma probabilidade 24 vezes maior de uma prova cruzada positiva de células B quando comparado com MFIs menores. Conclusões: Nossos resultados mostram uma forte associação entre o DSA MFI e o resultado do FCXM. Os dados aqui apresentados confirmam os resultados dos nossos estudos anteriores, justificando o padrão VXM utilizado pelo nosso centro, revelando-se uma boa ferramenta para agilizar a seleção de receptores de transplantes e facilitar a distribuição de órgãos de dadores nacionais.